Back to Authors

Encarnacion, Krystal

Mayo Clinic

Columbia University

Citations 1

The National Institute on Aging Alzheimer's Disease Family Based Study, an enriched resource for the scientific community
Faber, Kelley M., Weinfeld, Cory, Erickson, Abigail, Rosario, Pamela del, Potocki, Madison, Encarnacion, Krystal, O'Reilly, Amber, Villamizar, Jenverlys, Valdez, Olga, Gentsch, Jen, Navarro, Alexis, Orr, Victoria L, Payne, Sarah, Horner, Kelly, Weamer, Elise A., Figueroa, Katy, Elrayes, Karen, LaRoche, Ashley , Castro, Julia, Rumbaugh, Malia C., Chan, Amanda, Reyes‐Dumeyer, Dolly , Study, The Alzheimer's Disease Family Based, Rumbaugh, Malia

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S6 | Pages: No page available

10.1002/alz70860_107516 Get It

Abstract Background The National Institute on Aging Alzheimer's Disease Family Based Study (NIA‐ AD FBS) is a multi‐site, longitudinal study aimed to be a data and bio sample resource for investigators worldwide. Since its inception in 2002 the FBS goal has been to promote greater cooperation and sharing of clinical and biological resources among researchers. Methods The focus of the Family Based Study (FBS) has been the recruitment of families with at least two affected individuals and a third first degree relative with or without dementia and willing to participate. Participants are from different ethnic backgrounds including Caucasian, African American and Hispanics. The FBS study is actively recruiting both late onset (LOAD) and early onset Alzheimer's Disease (EOAD) families as well as conducting follow up evaluations every two years, approximately. Uniform assessments are completed across all sites and include DNA, Plasma, PaXgene and PBMC samples collection and brain autopsies whenever possible. We conduct both in person and remote evaluations and use the services of a mobile phlebotomy company to collect bio samples. In addition, we’ve created a protocol for genetic testing on the proband for EOAD families where an additional sample is sent to a CLIA approved lab and after genetic counseling, the presence or not of AD related mutations is disclosed to the families. Results To date, this cohort has recruited 1,756 families and acquired data from 9,682 family members. Families are from Caucasian, African Americans and Hispanics ethnic groups. The cohort has longitudinal clinical data, cognitive assessment, family history and bio samples available for sharing. Genotype data includes APOE, GWAS, WES, WGS, brain methylation, RNA sequencing and biomarkers data. Conclusion The NIA‐LOAD FBS study is the largest collection of familial Alzheimer's Disease worldwide and many genetic studies of Alzheimer's disease (AD) have included cases and controls from this dataset. Over 140 publications have used data and/or samples from FBS to address the genetics of Alzheimer's Disease. The enriched resources provided by this cohort are invaluable to the scientific community.